Developed by China, marketed by Italy. This is the binomial behind the request for evaluation by the Ema of the vaccine produced by the Chinese Sinovac: the Life’On of Pomezia, in fact, presented the necessary documentation so that the European drug agency can establish if and under what conditions it is possible to administer this anti-Covid vaccine also in EU.
Life’On is the vaccine branch of the Orofino group and should be responsible for managing the possible marketing of Sinova’s drug. EMA’s decision to initiate the evaluation is based on the preliminary results of laboratory studies (non-clinical data) and clinical studies. These studies suggest that the Chinese vaccine (not to be confused with Sinopharm’s) triggers the production of antibodies that target Sars-CoV-2. The EMA will evaluate the data as it becomes available to decide whether the benefits outweigh the risks.
Sinovac’s vaccine “should prepare the body to defend itself against Sars-CoV-2 infection”, writes the EMA, as “it contains Sars-CoV-2 which has been inactivated, i.e. killed, and cannot cause disease. “. This vaccine also contains an “adjuvant”, a substance that helps strengthen the immune response to the vaccine. When a person receives the vaccine, their immune system identifies the inactivated virus as foreign and makes antibodies against it. If the vaccinated person subsequently comes into contact with Sars-CoV-2, the immune system will recognize the virus and be ready to defend the body from it.